Can-Fite BioPharma Ltd. (CANF)
After hours:
| Previous Close | 1.9450 |
| Open | 1.9700 |
| Bid | 1.9400 x 1000 |
| Ask | 2.0700 x 1000 |
| Day's Range | 1.9100 - 2.0252 |
| 52 Week Range | 1.8100 - 4.6900 |
| Volume | |
| Avg. Volume | 111,382 |
| Market Cap | 12.01M |
| Beta (5Y Monthly) | 0.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6000 |
| Earnings Date | Nov 28, 2024 - Dec 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.33 |
GlobeNewswireProjected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that its veterinary partner Vetbiolix exercised its option and signed a development and commercialization agreement with Can-Fite f
- GlobeNewswire
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
Study will aim to establish safety and clinical efficacy PETACH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it received approval from the Israeli Ministry of Health (MoH) to conduct Phase IIa clinical trial with orally-administered Namodenoson in the treatment of pancreatic carci
Insider MonkeyIs Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts?
We recently published a list of 10 Best Rated Penny Stocks To Buy According to Analysts. In this article, we are going to take a look at where Can-Fite BioPharma Ltd. (NYSE:CANF) stands against the other best rated penny stocks. Penny stocks, often defined as shares trading for less than $5, present a high-risk, high-reward investment […]
